Who is a candidate for ChondroFiller injection in the hip?

The first question most patients and referring clinicians ask is a practical one: does the pattern of damage fit? ChondroFiller injection is designed for focal, structural cartilage loss — not generalised joint wear — and the formal CE-mark indication sets a clear starting point.

The lesion must reach ICRS (Outerbridge) Grade III or IV. Grade III means partial-thickness fissuring or fragmentation that has not yet reached bone; Grade IV means the cartilage has worn through entirely, exposing the underlying subchondral bone. Surface-level softening or early fissuring at Grade I or II does not meet the threshold, because the scaffold's regenerative mechanism depends on a structurally significant void to fill and stabilise.

Defect size matters as much as depth. Published criteria support lesions up to approximately 6 cm² in area. Beyond a diameter of roughly 2.5 cm, the defect becomes difficult to fill reliably via the injectable route, and the regenerative case weakens. Lesions should also be focal and relatively contained: diffuse cartilage loss spanning multiple joint surfaces — the hallmark of advanced osteoarthritis — falls outside the regenerative goal, though in Kellgren-Lawrence Grade III or IV joints the injection may still offer value as a collagen cushion to reduce friction and manage symptoms, with expectations framed accordingly.

In younger, active patients the most common presentation is anterosuperior acetabular damage driven by cam-type femoroacetabular impingement (FAI). Where FAI is present, the mechanical cause must be addressed at the same time — leaving the impingement untreated compromises any repair. Crucially, there is no published age ceiling for the injection pathway; suitability turns on lesion grade, defect size, and overall joint status rather than the patient's age alone.

What ChondroFiller injection actually does inside the joint

Once injected under ultrasound guidance, ChondroFiller behaves less like a patch applied from outside and more like a biological framework the body is invited to fill in.

The product is an acellular Type I collagen solution — it contains no donor cells of any kind. At body temperature the collagen polymerises within the defect, forming a stable three-dimensional matrix that conforms to the shape of the lesion. That matrix then does two jobs simultaneously: it provides physical scaffolding for incoming cells, and it emits chemotactic signals that draw the patient's own mesenchymal and chondral progenitor cells from the surrounding synovium and subchondral bone into the defect site. Over approximately three to six months those recruited cells remodel the scaffold into fibrocartilage-like repair tissue as the collagen gradually resorbs. This process is termed matrix-induced chondrogenesis; it does not guarantee hyaline cartilage — the repair tissue is fibrocartilage-like in character — but it targets the structural defect rather than masking its effects.

This distinguishes it from two other options patients often encounter. Hyaluronic acid viscosupplementation adds lubrication to the joint fluid but provides no structural matrix and recruits no repair cells. Autologous chondrocyte implantation (ACI) and its matrix variant (MACI) are genuinely regenerative but require two separate procedures: an initial biopsy to harvest the patient's chondrocytes, a laboratory culture phase, then a second operation for implantation. ChondroFiller injection achieves the regenerative aim in a single outpatient visit, without harvesting or culturing cells.

The injection procedure: what the outpatient visit involves

Arriving for the procedure, patients find themselves in an outpatient setting rather than an operating theatre. The collagen is delivered under ultrasound — or occasionally fluoroscopic — guidance, via a percutaneous injection, without surgical incisions or general anaesthesia.

What makes the technique genuinely demanding is the hip's anatomy. The joint is a deep, constrained ball-and-socket structure with far more restricted access than the knee; accurate placement over an acetabular or femoral head defect requires a clinician who combines image-guided injection skills with specific knowledge of ChondroFiller's handling properties and the local articular geometry. That combination is not yet widely available, and the choice of centre matters.

Once placed, the collagen begins polymerising at body temperature within the defect. Patients are generally advised to limit full weight-bearing and avoid high-impact loading for an initial recovery window to allow the forming matrix to stabilise — though specific post-injection protocols vary by clinician and defect characteristics, and individual guidance from the treating specialist takes precedence.

Some published hip studies — including Mazek (2021, JHPS) and Perez-Carro (2021, PMC8322278) — used arthroscopic theatre-based implantation as their delivery route. Those series remain part of the evidence base for ChondroFiller in the hip, but they describe a different pathway from the image-guided outpatient injection; what their findings show about clinical outcomes is examined in the following section.

What the published evidence shows

Three published studies form the hip-specific evidence base, and together they cover more anatomical ground than any single trial alone.

Mazek (2021, JHPS, n=26) remains the most methodologically rigorous, reporting a cohort of 26 patients who received arthroscopic ChondroFiller application to isolated acetabular lesions larger than 2 cm² alongside FAI correction. All had Tönnis Grade 0 or 1 background wear; the series deliberately excluded Grade 2–3 joints, where outcomes were predicted to be poor, and meaningful functional improvement was reported across the cohort. Perez-Carro (2021, PMC8322278) confirmed ChondroFiller as a viable approach for full-thickness acetabular defects and reported promising early results, but was explicit that longer-term outcome data were still needed. Raju (2025, PMC12514867) extended the evidence to focal chondral defects of the femoral head specifically — an anatomically distinct target from the acetabulum — reinforcing that the technique is not confined to one articular surface.

Across these studies and the manufacturer's Clinical Evaluation Report (Version 09, April 2025), 70–85% of treated patients achieve meaningful symptom relief lasting up to three to five years. That is the headline outcome figure, and it is worth holding onto as a reference point. The honest qualification is methodological rather than clinical: no randomised controlled trial exists, and follow-up data beyond five years remain sparse — a limitation ChondroFiller shares with most cartilage-repair techniques at this stage of adoption.

Knee cohort data, showing IKDC score improvements of approximately 30 points, lend biological confidence to the scaffold's chondrogenic mechanism. Those results do not replace hip-specific long-term trial evidence, but they support the underlying science.

Practical limitations and what they mean for patients

Access to ChondroFiller injection in the hip is currently constrained by geography, funding, and — for patients outside Europe — regulation. In the United States, the product does not hold FDA approval and cannot be accessed through licensed clinical channels. Within the UK, it is not funded by the NHS and falls outside the standard benefits of major private insurers, including Bupa and AXA; patients should plan for self-funding from the outset.

Even where funding is in place, the procedure requires a clinician who combines image-guided injection expertise with ChondroFiller-specific technique — a pairing that is not yet widely distributed across UK practice. Centre selection is therefore a material decision, not a formality.

On suitability, the most clinically significant caveat concerns background joint health. Mazek's 2021 surgical series (JHPS) excluded patients with Tönnis Grade 2–3 osteoarthritis, and that criterion reflected the regenerative ambition of the arthroscopic pathway used in that study. The injectable route carries different technical parameters, and the Mazek exclusion does not transfer automatically — but the degree of background degeneration materially influences what a ChondroFiller injection can achieve, and careful clinical assessment is essential before proceeding. Perez-Carro (2021, PMC8322278) similarly underlined the importance of patient selection and the continuing need for longer-term outcome data.

Safety is not the primary concern here: complaint rates across published series are approximately 0.06%. The limitations described in this section are about access, funding, and clinical fit — not risk to the patient.

Getting an assessment in London

The practical next step, for anyone whose situation maps to the profile described in this article — a focal ICRS Grade III or IV lesion, a defect within the supported size range, manageable background joint health, and any underlying mechanical cause that can be corrected at the same time — is a specialist consultation built around imaging review and clinical examination.

Assessment at the London Cartilage Clinic (Harley Street) begins with MRI to characterise defect grade, size, and surrounding joint status. That information, read alongside clinical examination and a structured discussion of activity level and symptom burden, determines whether the injectable collagen scaffold pathway is appropriate or whether a different route — conservative management, a surgical cartilage restoration procedure, or joint replacement — would better serve the patient's goals.

Professor Paul Y. F. Lee leads the cartilage service and has specific expertise in image-guided injection techniques for focal hip cartilage defects. Patients based outside London may find the group's Lincolnshire and Grantham sites, accessible through MSK Doctors, a more practical starting point.

An initial consultation can be booked at londoncartilage.com.